SpringerProtocols: Abstract: Cytochrome P450-Based Gene Therapies for Cancer

Cytochrome P450-Based Gene Therapies for Cancer

By: E. Antonio Chiocca², David J. Waxman³

Abstract

Full Text

Download PDF (193K)

Cytochrome P450 (CYP) is comprosed of a family of hemeprotein monooxygenases that catalyze reactions as diverse as the biosynthesis of steroid hormones, metabolism of fat-soluble vitamins, oxidation of unsaturated fatty acids, and metabolism of drugs, pollutants, and other xenobiotics (for a review, see ref. 1). About 55 CYP genes, grouped into 17 gene families, are present in the human genome. CYPs belonging to gene families 1, 2, and 3 are particularly active in drug and xenobiotic metabolism and are most abundantly expressed in the liver and other tissues that come in contact with foreign chemicals. Large interindividual variations in CYP expression and, consequently, CYP-dependent drug metabolism are seen in humans, as a result of both genetic and environmental factors.

Affiliation(s): (2) Molecular Neuro-Oncology Laboratory, Neurosurgery Service, Massachusetts General Hospital, Harvard Medical School, Boston, MA
(3) Division of Cell and Molecular Biology, Department of Biology, Boston University, Boston, MA

Book Title: Suicide Gene Therapy: Methods and Reviews

Series: Methods in Molecular Medicine | Volume: 90 | Pub. Date: Nov-04-2003 | Page Range: 203-222 | DOI: 10.1385/1-59259-429-8:203

Subject: Genetics/Genomics

References

Download References

1.	Hasler, J. A. (1999) Pharmacogenetics of cytochromes P450. Mol. Aspects Med. 20, 12–24, 25–137.

2.	Kawajiri, K., Eguchi, H., Nakachi, K., Sekiya, T., and Yamamoto, M. (1996) Association of CYP1A1 germ line polymorphisms with mutations of the p53 gene in lung cancer. Cancer Res. 56, 72–76.

3.	Sladek, N. E. (1988) Metabolism of oxazaphosphorines. Pharmacol. Ther. 37, 301–355.

4.	Jounaidi, Y., Hecht, J. E., and Waxman, D. J. (1998) Retroviral transfer of human cytochrome P450 genes for oxazaphosphorine-based cancer gene therapy. Cancer Res. 58, 4391–4401.

5.	Chang, T. K., Yu, L., Goldstein, J. A., and Waxman, D. J. (1997) Identification of the polymorphically expressed CYP2C19 and the wild-type CYP2C9-ILE359 allele as low-K _m catalysts of cyclophosphamide and ifosfamide activation. Pharmacogenetics 7, 211–221.

6.	Harris, J. W., Rahman, A., Kim, B. R., Guengerich, F. P., and Collins, J. M. (1994) Metabolism of taxol by human hepatic microsomes and liver slices: participation of cytochrome P450 3A4 and an unknown P450 enzyme. Cancer Res. 54, 4026–4035.

7.	Crewe, H. K., Ellis, S. W., Lennard, M. S., and Tucker, G. T. (1997) Variable contribution of cytochromes P450 2D6, 2C9 and 3A4 to the 4-hydroxylation of tamoxifen by human liver microsomes. Biochem. Pharmacol. 53, 171–178.

8.	Shet, M. S., McPhaul, M., Fisher, C. W., Stallings, N. R., and Estabrook, R. W. (1997) Metabolism of the antiandrogenic drug (Flutamide) by human CYP1A2. Drug Metab. Dispos. 25, 1298–1303.

9.	Wei, M. X., Tamiya, T., Chase, M., et al. (1994) Experimental tumor therapy in mice using the cyclophosphamide-activating cytochrome P450 2B1 gene. Hum. Gene Ther. 5, 969–978.

10.	Colvin, O. M. (1999) An overview of cyclophosphamide development and clinical applications. Curr. Pharm. Des. 5, 555–560.

11.	Clarke, L. and Waxman, D. J. (1989) Oxidative metabolism of cyclophosphamide: identification of the hepatic monooxygenase catalysts of drug activation. Cancer Res. 49, 2344–2350.

12.	Bryant, J., Clegg, A., and Milne, R. (2001) Systematic review of immunomodulatory drugs for the treatment of people with multiple sclerosis: is there good quality evidence on effectiveness and cost? J. Neurol. Neurosurg. Psychiatry 70, 574–579.

13.	Genka, S., Deutsch, J., Stahle, P. L., et al. (1990) Brain and plasma pharmacokinetics and anticancer activities of cyclophosphamide and phosphoramide mustard in the rat. Cancer Chemother. Pharmacol. 27, 1–7.

14.	Levine, E. S., Friedman, H. S., Griffith, O. W., Colvin, O. M., Raynor, J. H., and Lieberman, M. (1993) Cardiac cell toxicity induced by 4-hydroperoxycyclophosphamide is modulated by glutathione. Cardiovasc. Res. 27, 1248–1253.

15.	Schuster, J. M., Friedman, H. S., Archer, G. E., et al. (1993) Intraarterial therapy of human glioma xenografts in athymic rats using 4-hydroperoxycyclophosphamide. Cancer Res. 53, 2338–2343.

16.	Huang, Z., Roy, P., and Waxman, D. J. (2000) Role of human liver microsomal CYP3A4 and CYP2B6 in catalyzing N-dechloroethylation of cyclophosphamide and ifosfamide. Biochem. Pharmacol. 59, 961–972.

17.	Chang, T. K., Weber, G. F., Crespi, C. L., Waxman, D. J., (1993) Differential activation of cyclophosphamide and ifosphamide by cytochromes P-450 2B and 3A in human liver microsomes. Cancer Res. 53, 5629–5637.

18.	Moolten, F. L., Wells, J. M., Heyman, R. A., and Evans, R. M. (1990) Lymphoma regression induced by ganciclovir in mice bearing a herpes thymidine kinase transgene. Hum. Gene Ther. 1, 125–134.

19.	Takamiya, Y., Short, M. P., Ezzeddine, Z. D., Moolten, F. L., Breakefield, X. O., and Martuza, R. L. (1992) Gene therapy of malignant brain tumors: a rat glioma line bearing the herpes simplex virus type 1-thymidine kinase gene and wild type retrovirus kills other tumor cells. J. Neurosci. Res. 33, 493–503.

20.	Moolten, F. L. and Wells, J. M. (1990) Curability of tumors bearing herpes thymidine kinase genes transferred by retroviral vectors. J. Natl. Cancer Inst. 82, 297–300.

21.	Chung, R. Y. and Chiocca, E. A. (1998) Gene therapy for tumors of the central nervous system. Surg. Oncol. Clin. North Am. 7, 589–602.

22.	Wildner, O. (1999) In situ use of suicide genes for therapy of brain tumours. Ann. Med. 31, 421–429.

23.	Harsh, G. R., Deisboeck, T. S., Louis, D. N., et al. (2000) Thymidine kinase activation of ganciclovir in recurrent malignant gliomas: a gene-marking and neuropathological study. J. Neurosurg. 92, 804–811.

24.	Chen, L. and Waxman, D. J. (1995) Intratumoral activation and enhanced chemotherapeutic effect of oxazaphosphorines following cytochrome P-450 gene transfer: development of a combined chemotherapy/cancer gene therapy strategy. Cancer Res. 55, 581–589.

25.	Chen, L., Waxman, D. J., Chen, D., and Kufe, D. W. (1996) Sensitization of human breast cancer cells to cyclophosphamide and ifosfamide by transfer of a liver cytochrome P450 gene. Cancer Res. 56, 1331–1340.

26.	Freeman, S. M., Abboud, C. N., Whartenby, K. A., et al. (1993) The “bystander effect” tumor regression when a fraction of the tumor mass is genetically modified. Cancer Res. 53, 5274–5283.

27.	Culver, K. W., Ram, Z., Wallbridge, S., Ishii, H., Oldfield, E. H., and Blaese, R. M. (1992) In vivo gene transfer with retroviral vector-producer cells for treatment of experimental brain tumors. Science 256, 1550–1502.

28.	Tapscott, S. J., Miller, A. D., Olson, J. M., Berger, M. S., Groudine, M., and Spence, A. M. (1994) Gene therapy of rat 9L gliosarcoma tumors by transduction with selectable genes does not require drug selection. Proc. Natl. Acad. Sci. USA 91, 8185–8189.

29.	Barba, D., Hardin, J., Sadelain, M., and Gage, F. H. (1994) Development of anti-tumor immunity following thymidine kinase-mediated killing of experimental brain tumors. Proc. Natl. Acad. Sci. USA 91, 4348–4352.

30.	Felzmann, T., Ramsey, W. J., and Blaese, R. M. (1997) Characterization of the antitumor immune response generated by treatment of murine tumors with recombinant adenoviruses expressing HSVtk, IL-2, IL-6 or B7-1. Gene Ther. 4, 1322–1329.

31.	Mullen, C. A., Coale, M. M., Lowe, R., and Blaese, R. M. (1994) Tumors expressing the cytosine deaminase suicide gene can be eliminated in vivo with 5-fluorocytosine and induce protective immunity to wild type tumor. Cancer Res. 54, 1503–1506.

32.	Mullen, C. A., Kilstrup, M., and Blaese, R. M. (1992) Transfer of the bacterial gene for cytosine deaminase to mammalian cells confers lethal sensitivity to 5-fluorocytosine: a negative selection system. Proc. Natl. Acad. Sci. USA 89, 33–37.

33.	Wei, M. X., Tamiya, T., Rhee, R. J., Breakefield, X. O., and Chiocca, E. A. (1995) Diffusible cytotoxic metabolites contribute to the in vitro bystander effect associated with the cyclophosphamide/cytochrome P450 2B1 cancer gene therapy paradigm. Clin Cancer Res. 1, 1171–1177.

34.	Ichikawa, T., Petros, W. P., Ludeman, S. M., et al. (2001) Intraneoplastic polymer-based delivery of cyclophosphamide for intratumoral bioconversion by a replicating oncolytic viral vector. Cancer Res. 61, 864–868.

35.	Kuriyama, S., Masui, K., Sakamoto, T., et al. (1998) Bystander effect caused by cytosine deaminase gene and 5-fluorocytosine in vitro is substantially mediated by generated 5-fluorouracil. Anticancer Res. 18, 3399–3406.

36.	Connors, T. A. (1995) The choice of prodrugs for gene directed enzyme prodrug therapy of cancer. Gene Ther. 2, 702–709.

37.	Ram, Z., Culver, K. W., Oshiro, E. M., et al. (1997) Therapy of malignant brain tumors by intratumoral implantation of retroviral vector-producing cells. Nature Med. 3, 1354–1361.

38.	Puumalainen, A. M., Vapalahti, M., Agrawal, R. S., et al. (1998) Beta-galactosidase gene transfer to human malignant glioma in vivo using replication-deficient retroviruses and adenoviruses. Hum. Gene Ther. 9, 1769–1774.

39.	Smith, E. R. and Chiocca, E. A. (2000) Oncolytic viruses as novel anticancer agents: turning one scourge against another. Expert Opin. Invest. Drugs 9, 311–327.

40.	Chung, R. Y., Saeki, Y., and Chiocca, E. A. (1999) B-myb promoter retargeting of herpes simplex virus gamma34.5 gene-mediated virulence toward tumor and cycling cells. J. Virol. 73, 7556–7564.

41.	Suzuki, K., Fueyo, J., Krasnykh, V., Reynolds, P. N., Curiel, D. T., and Alemany, R. (2001) A conditionally replicative adenovirus with enhanced infectivity shows improved oncolytic potency. Clin. Cancer Res. 7, 120–126.

42.	Aghi, M., Chou, T. C., Suling, K., Breakefield, X. O., and Chiocca, E. A. (1999) Multimodal cancer treatment mediated by a replicating oncolytic virus that delivers the oxazaphosphorine/rat cytochrome P450 2B1 and ganciclovir/herpes simplex virus thymidine kinase gene therapies. Cancer Res. 59, 3861–3865.

43.	Ichikawa, T. and Chiocca, E. A. (2001) Comparative analyses of transgene expression mediated by a replication-conditional vs. defective viral vector. Cancer Res. 61, 5336–5339.

44.	Jacobson, J. G., Leib, D. A., Goldstein, D. J., et al. (1989) A herpes simplex virus ribonucleotide reductase deletion mutant is defective for productive acute and reactivatable latent infections of mice and for replication in mouse cells. Virology 173, 276–283.

45.	Coen, D. M., Goldstein, D. J., and Weller, S. K. (1989) Herpes simplex virus ribonucleotide reductase mutants are hypersensitive to acyclovir. Antimicrob. Agents Chemother. 33, 1395–1399.

46.	Rampling, R., Cruickshank, G., Papanastassiou, V., et al. (2000) Toxicity evaluation of replication-competent herpes simplex virus (ICP 34.5 null mutant 1716) in patients with recurrent malignant glioma. Gene Ther. 7, 859–866.

47.	Markert, J. M., Medlock, M. D., Rabkin, S. D., et al. (2000) Conditionally replicating herpes simplex virus mutant, G207 for the treatment of malignant glioma: results of a phase I trial. Gene Ther. 7, 867–874.

48.	Chase, M., Chung, R. Y., and Chiocca, E. A. (1998) An oncolytic viral mutant that delivers the CYP2B1 transgene and augments cyclophosphamide chemotherapy. Nature Biotechnol. 16, 444–448.

49.	Ikeda, K., Ichikawa, T., Wakimoto, H., et al. (1999) Oncolytic virus therapy of multiple tumors in the brain requires suppression of innate and elicited antiviral responses. Nature Med. 5, 881–887.

50.	Ikeda, K., Wakimoto, H., Ichikawa, T., et al. (2000) Complement depletion facilitates the infection of multiple brain tumors by an intravascular, replication-conditional herpes simplex virus mutant. J. Virol. 74, 4765–4775.

51.	Aghi, M., Kramm, C. M., Chou, T. C., Breakefield, X. O., and Chiocca, E. A. (1998) Synergistic anticancer effects of ganciclovir/thymidine kinase and 5-fluorocytosine/cytosine deaminase gene therapies. J. Natl. Cancer Inst. 90, 370–380.

52.	Chou, T. C., Motzer, R. J., Tong, Y., and Bosl, G. J. (1994) Computerized quantitation of synergism and antagonism of taxol, topotecan, and cisplatin against human teratocarcinoma cell growth: a rational approach to clinical protocol design. J. Natl. Cancer Inst. 86, 1517–1524.

53.	Andersson, B. S., Sadeghi, T., Siciliano, M. J., Legerski, R., and Murray, D. (1996) Nucleotide excision repair genes as determinants of cellular sensitivity to cyclophosphamide analogs. Cancer Chemother. Pharmacol. 38, 406–416.

54.	Li, L., Keating, M. J., Plunkett, W., and Yang, L. Y. (1997) Fludarabine-mediated repair inhibition of cisplatin-induced DNA lesions in human chronic myelogenous leukemia-blast crisis K562 cells: induction of synergistic cytotoxicity independent of reversal of apoptosis resistance. Mol. Pharmacol. 52, 798–806.

55.	Ilsley, D. D., Lee, S. H., Miller, W. H., and Kuchta, R. D. (1995) Acyclic guanosine analogs inhibit DNA polymerases alpha, delta, and epsilon with very different potencies and have unique mechanisms of action. Biochemistry 34, 2504–2510.

56.	Kammertoens, T., Gelbmann, W., Karle, P., et al. (2000) Combined chemotherapy of murine mammary tumors by local activation of the prodrugs ifosfamide and 5-fluorocytosine. Cancer Gene Ther. 7, 629–636.

57.	Anon. (1998) Gliadel wafers for treatment of brain tumors. Med. Lett. Drugs Ther. 40, 92.

58.	Chen, L., Yu, L. J., and Waxman, D. J. (1997) Potentiation of cytochrome P450/cyclo-phosphamide-based cancer gene therapy by coexpression of the P450 reductase gene. Cancer Res. 57, 4830–4837.

59.	Jounaidi, Y. and Waxman, D. J. (2000) Combination of the bioreductive drug tirapazamine with the chemotherapeutic prodrug cyclophosphamide for P450/P450-reductase-based cancer gene therapy. Cancer Res. 60, 3761–3769.

60.	Huang, Z., Raychowdhury, M. K., and Waxman, D. J. (2000) Impact of liver P450 reductase suppression on cyclophosphamide activation, pharmacokinetics and antitumoral activity in a cytochrome P450-based cancer gene therapy model. Cancer Gene Ther. 7, 1034–1042.

61.	Huang, Z. and Waxman, D. J. (2001) Modulation of cyclophosphamide-based cytochrome P450-based gene therapy using liver P450 inhibitors. Cancer Gene Ther. 8, 450–458.

62.	Browder, T., Butterfield, C. E., Kraling, B. M., et al. (2000) Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer. Cancer Res. 60, 1878–1886.

63.	Jounaidi, Y. and Waxman, D. J. (2001) Frequent, moderate-dose cyclophosphamide administration improves the efficacy of cytochrome P-450/cytochrome P-450 reductasebased cancer gene therapy. Cancer Res. 61, 4437–4444.

64.	Lohr, M., Muller, P., Karle, P., et al. (1998) Targeted chemotherapy by intratumour injection of encapsulated cells engineered to produce CYP2B1, an ifosfamide activating cytochrome P450. Gene Ther. 5, 1070–1078.

65.	Griffiths, L., Binley, K., Iqball, S., et al. (2000) The macrophage—a novel system to deliver gene therapy to pathological hypoxia. Gene Ther. 7, 255–2562.

66.	Rainov, N. G., Dobberstein, K. U., Sena-Esteves, M., et al. (1998) New prodrug activation gene therapy for cancer using cytochrome P450 4B1 and 2-aminoanthracene/4-ipomeanol. Hum Gene Ther. 9, 1261–1273.

67.	McCarthy, H. O., Yakkundi, A., McErlane, V., et al. (2003) Bioreductive GDEPT using cytochrome P450 3A4 in combination with AQ4N. Cancer Gene Ther. 10, 40–48.

68.	Thatcher, N. J., Edwards, R. J., Lemoine, N. R., Doehmer, J., and Davies, D. S. (2000) The potential of acetaminophen as a prodrug in gene-directed enzyme prodrug therapy. Cancer Gene Ther. 7, 521–525.

69.	Lohr, M., Hoffmeyer, A., Kroger, J., et al. (2001) Microencapsulated cell-mediated treatment of inoperable pancreatic carcinoma. Lancet 357, 1591–1592.

70.	Schwartz, P. S. and Waxman, D. J. (2001) Cyclophosphamide induces caspase 9-dependent apoptosis in 9L tumor cells. Mol. Pharmacol. 60, 1268–1279.

71.	Antonio Chiocca, E. (2002) Oncolytic viruses. Nat. Rev. Cancer 2, 938–950.

72.	Wakimoto, H., Ikeda, K., Abe T., et al. (2002) The complement response against an oncolytic virus is species-specific in its activation pathways. Mol. Ther. 5, 275–282.

73.	Wakimoto, H., Johnson, P. R., Knipe, D. M., Chiocca, E. A. (2003) Effects of innate immunity on herpes simplex virus and its ability to kill tumor cells. Gene Ther. 10, 983–990.

Comments (Loading...)

Post comment/View all comments